Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma
Autore:
Maehara, Y; Kakeji, Y; Watanabe, A; Baba, H; Kusumoto, H; Kohnoe, S; Sugimachi, K;
Indirizzi:
Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 8128582, Japan Kyushu Univ Fukuoka Japan 8128582 d, Dept Surg 2, Fukuoka 8128582, Japan
Titolo Testata:
CANCER
fascicolo: 2, volume: 85, anno: 1999,
pagine: 302 - 308
SICI:
0008-543X(19990115)85:2<302:CIOSAA>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-SUPPRESSOR GENE; CELLULAR PROTEIN P53; BREAST-CANCER; LUNG-CANCER; COLORECTAL-CANCER; IMMUNE-RESPONSE; CIRCULATING ANTIBODIES; ONCOGENE PRODUCT; OVEREXPRESSION; EXPRESSION;
Keywords:
gastric cancer; anti-p53 antibodies; p53 overexpression; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Maehara, Y Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 8128582, Japan Kyushu Univ Fukuoka Japan 8128582 g 2, Fukuoka 8128582, Japan
Citazione:
Y. Maehara et al., "Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma", CANCER, 85(2), 1999, pp. 302-308

Abstract

BACKGROUND. Mutations of p53 can lead to the production of anti-p53 antibodies in sera of cancer patients. Before this study, the value of preoperative serum anti-p53 antibodies in determining the prognoses of patients with gastric carcinoma had yet to be determined. METHODS. The authors used a highly specific enzyme-linked immunosorbent assay (ELISA) kit (Pharma Cell, France) to determine the preoperative presence of serum anti-p53 antibodies in 120 patients with gastric carcinoma. The relation between the positivity of serum anti-p53 antibodies and p53 abnormal staining of gastric carcinoma tissues was examined. Clinicopathologic characteristics and prognoses of these patients were given attention. RESULTS. Anti-p53 antibodies were detected in 19.2%(23 of 120) of these patients with gastric carcinoma Among those who were positive for anti-p53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti-p53 antibodies. Regarding other factors, there were no differences between those who were positive or negative for anti-p53 antibodies. Gastric carcinoma tissues had a 60.9%(14 of 23) positivity rate of p53 staining with anti-p53 antibodies and a 33.0%(32 of 97) negativity rate, and this difference was statistically significant (P < 0.05). The survival time ofpatients with anti-p53 antibodies in their sera was shorter than that of subjects with sera negative for anti-p53 antibodies (P < 0.05). The presenceof anti-p53 antibodies was not an independent prognostic factor in multivariate analysis. CONCLUSIONS. Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show it poorer prognosis for surgically treated patients with gastric carcinoma. (C) 1999 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 22:54:08